NASDAQ$UTHR
United Therapeutics Corp · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
United Therapeutics' financial performance was announced for Q2 2020, revealing a mix of challenges and successes.
United Therapeutics reported a decrease in total revenues by 3% compared to the same quarter last year, with net income also declining by 48%. However, Orenitram revenue saw a significant increase of 40% year-over-year. The company is preparing for potential growth with upcoming product launches and label expansions.
- Total revenues decreased by 3% year-over-year, totaling $362 million.
- Net income declined by 48% compared to the same quarter last year, reaching $107.1 million.
- Orenitram revenue increased by 40% year-over-year, driven by increased quantities sold after a label update.
- The company submitted the INCREASE study results to the FDA, anticipating revised labeling for Tyvaso.
Headline financials
Revenue & EPS history
United Therapeutics · Revenue · Quarterly
$362M
Revenue by segment
United Therapeutics · $362M total across 5 segments · Q2 2020
- Nebulized Tyvaso$119M+8.8%32.9%
- Remodulin$119M-23.6%32.9%
- Orenitram$75.4M+39.6%20.8%
- Unituxin$29M+15.5%8.0%
- Adcirca$19.4M-33.3%5.4%
Forward guidance
United Therapeutics is focusing on launching new products and expanding the label for Tyvaso. However, the COVID-19 pandemic has caused delays in the commercial sales of Remunity Pump.
Tailwinds
- Tyvaso is expected to grow due to the INCREASE study results.
- The INCREASE study results were submitted to the FDA, expecting revised labeling reflecting the outcome.
- The company is working to commence commercial sales of the Remunity Pump in the near-term.
- Clinical studies remain open, and enrollment of new patients has resumed at select study sites for certain studies.
- The company is expanding efforts to enter into contracts with additional clinical study sites and complete other site activation activities for certain studies.
Headwinds
- Manufacturing and regulatory requests are causing delays in the launch of Remunity Pump and Implantable System for Remodulin.
- The timing of commercial sales of Remunity Pump has been delayed due to pandemic-related issues.
- The FDA issued a complete response letter (CRL) related to the NDA for Trevyent.
- The launch of Implantable System for Remodulin is delayed until 2021.
- Completion and data readouts for several ongoing and planned studies are expected to be delayed due to the pandemic.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
+0.6%
Avg return
Earnings day
+0.2%
Avg return
5 days after
+1.1%
Avg return
30 days after
57%
39 / 68 earnings
Positive
+16.2%
Q3 2022
Best reaction
-13.0%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.3% | -0.4% | -4.0% | |
| Q4 2025 | +13.1% | +8.5% | +10.4% | |
| Q3 2025 | +9.7% | +5.6% | +17.0% | |
| Q1 2025 | +0.8% | -0.7% | +6.0% | |
| Q4 2024 | -10.8% | -13.3% | -14.1% | |
| Q3 2024 | +6.0% | +6.8% | +5.0% | |
| Q2 2024 | -2.9% | -3.5% | +7.7% | |
| Q1 2024 | +10.2% | +11.2% | +17.4% | |
| Q4 2023 | +1.6% | +4.4% | +11.1% | |
| Q3 2023 | +2.4% | +2.4% | +8.0% | |
| Q2 2023 | -3.4% | -1.0% | -5.0% | |
| Q1 2023 | -5.7% | -8.0% | -5.1% | |
| Q4 2022 | -2.7% | -3.3% | -13.8% | |
| Q3 2022 | +16.2% | +16.8% | +22.0% | |
| Q2 2022 | -1.5% | -2.7% | -0.8% | |
| Q1 2022 | +4.1% | -0.6% | +27.2% | |
| Q4 2021 | -13.0% | -14.0% | -9.5% | |
| Q3 2021 | +4.8% | +5.1% | -3.2% | |
| Q2 2021 | +13.7% | +15.0% | +16.7% | |
| Q1 2021 | -1.7% | -2.8% | -9.9% | |
| Q4 2020 | -2.1% | -0.6% | -0.7% | |
| Q3 2020 | +5.6% | +8.6% | +9.8% | |
| Q2 2020 | +0.3% | +2.9% | -6.3% | |
| Q1 2020 | -0.2% | +2.0% | +7.5% | |
| Q4 2019 | -10.7% | -8.0% | -19.1% | |
| Q3 2019 | +3.3% | +3.6% | +6.1% | |
| Q2 2019 | +4.5% | -0.5% | +3.8% | |
| Q1 2019 | -1.3% | -1.9% | -18.1% | |
| Q4 2018 | +3.6% | -1.5% | -3.8% | |
| Q3 2018 | -6.2% | -6.2% | -3.7% | |
| Q2 2018 | +0.3% | +0.7% | +0.1% | |
| Q1 2018 | -8.3% | -8.3% | -4.2% | |
| Q4 2017 | -12.9% | -14.1% | -20.4% | |
| Q3 2017 | +0.2% | +0.8% | +5.1% | |
| Q2 2017 | -2.3% | -2.6% | -2.2% | |
| Q1 2017 | -1.0% | +1.0% | -2.2% | |
| Q4 2016 | -12.2% | -9.2% | -16.6% | |
| Q3 2016 | +4.5% | +6.0% | +19.0% | |
| Q2 2016 | +6.9% | +11.2% | +7.6% | |
| Q1 2016 | -10.6% | — | — | |
| Q4 2015 | -4.2% | — | — | |
| Q3 2015 | +8.8% | — | — | |
| Q2 2015 | +0.8% | — | — | |
| Q1 2015 | -4.4% | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | -1.9% | — | — | |
| Q2 2014 | +2.7% | — | — | |
| Q1 2014 | +12.4% | — | — | |
| Q4 2013 | -4.1% | — | — | |
| Q3 2013 | +3.8% | — | — | |
| Q2 2013 | +2.7% | — | — | |
| Q1 2013 | -1.6% | — | — | |
| Q4 2012 | +2.7% | — | — | |
| Q3 2012 | +2.9% | — | — | |
| Q2 2012 | +8.3% | — | — | |
| Q1 2012 | +0.8% | — | — | |
| Q4 2011 | -0.9% | — | — | |
| Q3 2011 | +8.0% | — | — | |
| Q2 2011 | +5.0% | — | — | |
| Q1 2010 | -5.3% | — | — | |
| Q1 2011 | +0.8% | — | — | |
| Q4 2008 | +1.8% | — | — | |
| Q4 2010 | +1.8% | — | — | |
| Q3 2009 | +8.0% | — | — | |
| Q3 2010 | +8.0% | — | — | |
| Q4 2009 | -8.2% | — | — | |
| Q2 2010 | -8.2% | — | — | |
| Q2 2009 | -8.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro